Overview

Fundamentals

Financial Fundamentals

Review latest financial statements, quality scores, TTM ratios, and peer context for this stock.

Company SELLAS Life Sciences Group Inc Healthcare / Biotechnology
Latest report Q1 2026 2026-03-31
Currency USD Local financial statement archive
Filing Open filing 2026-05-12
Revenue -
Gross profit -
Operating income $-9.25M
Net income $-8.41M
Free cash flow -
Total debt -
Altman Z 111.36
Piotroski 2.00

Statements

Latest financial statement highlights

Income statement

Revenue -
Cost of revenue -
Gross profit -
Operating expenses $9.25M
EBITDA $-8.41M
Operating income $-9.25M
Income before tax $-8.41M
Net income $-8.41M
EPS -0.0487

Cash flow

Operating cash flow -
Capital expenditure -
Free cash flow -
Dividends paid -
Share repurchases -
Net cash change -

Balance sheet

Cash -
Current assets -
Total assets -
Current liabilities -
Total liabilities -
Total debt -
Net debt -
Stockholders equity -

Ratios

Period and TTM ratios

Metric Period TTM
Gross margin - 0.00%
Operating margin - 0.00%
Net margin - 0.00%
Return on equity - -47.12%
Current ratio - 17.22
Quick ratio - 17.22
P/E - -39.73
Price / sales - 0
Debt / equity - 0.00811
Interest coverage - 0

Peer context

Ratio comparison

Gross margin Best GNFT 101.36% SLS 0.00% Peer average 59.71%
Return on equity Best NTHI 284.28% SLS -47.12% Peer average -3.35%
Current ratio Best TARA 15.69 SLS 17.22 Peer average 5.02
Debt / equity Best ARMP -1.199 SLS 0.00811 Peer average 0.398
P/E Best GNFT -10.09 SLS -39.73 Peer average -4.42